Marksans Pharma Share Price Target 2024-2030 Fundamentals & Quarterly Results

Marksans Pharma Share Price Target 2024, 2025, 2026, 2027, 2028, 2029, 2030 Fundamentals & Quarterly Results – Marksans Pharma leads the way in the pharmaceutical industry as it maintains an approach focused on the customers. With a specialization in over-the-counter drugs as well as prescription medication, Marksans has successfully established itself in tight regulatory markets.Marksans Pharma Share Price Target

Latest Update – In the Q1 2024-2025, Marksans Pharma Ltd’s net profit increased by ₹88.75 Crores, which is a 29.26% increase when compared with the same period last year. From a quarter-on-quarter perspective, Marksans Pharma Ltd has grown its net profit by 13.36% over the past three months.

Marksans Pharma Overview

Marksans Pharma Limited is an Indian pharmaceutical company. It is involved in the manufacture and sale of research pharmaceutical formulations as its core activity. Across multiple therapeutic areas, it offers products for pain control, coughs and colds, heart disease or central nervous system disorders, metabolism improvement and protecting the gastrointestinal tract, balancing hormones in humans, as well as alleviating allergies.

Company Name Marksans Pharma Ltd
Listed at NSE & BSE
Head Office 11th Floor, Grandeur, Opp Gundecha Symphony, Off Veera Desai Road, Andheri West, Mumbai 400053
Board Of Directors
  • Chairman – Mark Saldanha
  • Managing Director – Mark Saldanha
  • Company Secretary – Harshavardhan Panigrahi
  • Non Executive Independent Director  – Seetharama Raju Buddharaju
  • Non Executive Independent Director – Digant Mahesh Parikh
  • Non Executive Independent Director – Abhinna Sundar Mohanty
  • Non Executive Independent Director  – Shailaja Vardhan
  • Whole Time Director – Sandra Saldanha
  • Whole Time Director – Varddhman Vikramaditya Jain
  • Non Independent & Non Executive Director – Sunny Sharma
Official Website marksanspharma.com

Also Check Tata Elxsi Share Price Target

Marksans Pharma Business Profile

Marksans Pharma manufactures drug formulations for the pharmaceuticals sector. Its main areas of interest are in OTC and prescribed drugs which are widely used in a broad spectrum of applications including treatments for cancers, infections in the stomach, diabetes, inflammations, heart related issues, pain relievers, among others.

Also Check Union Bank Share Price Target

Product Portfolio

The company has over one thousand five hundred stock-keeping units and more than three hundred products in different formulations, including tablets (plain, enteric coated and film coated), as well as hard & soft gelatin capsules and oral liquids or ointments.

Also Check Himadri Share Price Target

Operation Overview

USA – In June 2015, Co bought Time Cap Labs Inc. This particular WoS is servicing the region. Their product lines are divided across Private Label OTC, Generic Prescription Drugs – with over 50 items on the list thereof. Customers range from Target to Walmart to Walgreens and Kroger among others.

Also Check IFCI Share Price Target

UK and Europe- The region is serviced by two subsidiaries owned by The Co, which are Relonchem and Bells Healthcare. Private label & branded cough liquids in the UK are mainly from Bells Healthcare which is the biggest manufacturer while Relonchem provides a wide selection of own label healthcare pharmaceutical products. This has improved its distribution and penetration into the UK market because the Co has partnered with key retailers in the UK like Tesco, Asda, Morrisons, Coop and Boots.

Also Check Bank of Maharashtra Share Price Target

Australia and New Zealand – Marksans Pharma collaborates with major retailers and pharmacies in Australia such as Woolworths Ltd., Coles Mayer Ltd., Aldis, Metcash and Fauldings as well as through partnership between Teva/ Arrow Pharma for the New Zealand pharmaceutical market.

New Products List

USA – 32 products are in the pipeline, 20 are oral solids, 12 are ointments and creams, 4 are Softgels.
UK – Planned 34 new filings in next 3 yrs. + 16 products awaiting approval.
Australia and New Zealand – 10 products are in the pipeline and expected to be launched
over the next 2 yrs.
ROW – 124 products approved, 120 awaiting
approval & 108 in the pipeline.

Also Check Olectra Greentech Share Price Target

Acquisition & Capex

In April, 2023, Marksans acquired Teva’s manufacturing unit in a bid to expand its current capacities by a total capex of Rs. 200 crs. For FY24, preacquisition of Rs. 160 crs. by the company was already underway, which included Rs 78 crs acquisition expenses Capex FY23 amounted to approximately 53 crores.

Also Check CDSL Share Price Target

New Approval

on October 23, the company received US FDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC). In speech of AstraZeneca Pharmaceuticals LP, the Nexium 24 HR Delayed Release Capsules are bio equivalent. In Goa the production of the new drug will take place.

Also Check IDFC First Bank Share Price Target

Subsidiaries

1.  Marksans Holdings Ltd (UK) – WOS
2.  Marksans Pharma Inc (US) – WOS
3.  Nova Pharmaceuticals Australasia Pty Ltd. (Australia) – 60% stake
4.  Access Healthcare for Medical Products LLC (UAE) – WOS

Also Check Orient Green Power Share Price Target

Marksans Pharma Fundamentals & Quarterly Results

Market Cap ₹ 7,509 Cr.
Current Price ₹ 166
High / Low ₹ 186 / 70.2
Stock P/E 23.7
Book Value ₹ 41.4
Dividend Yield 0.30 %
ROCE 22.2 %
ROE 18.6 %
Face Value ₹ 1.00
Debt to equity 0.06
Debt Capacity 0.14
Debt preceding year ₹ 111 Cr.
Debt ₹ 111 Cr.
Reserves ₹ 1,830 Cr.
EPS ₹ 7.00
EPS last year ₹ 5.88
Pledged percentage 0.00 %
FCF Prev Ann ₹ 53.0 Cr.
EVEBITDA 13.8
Industry PE 27.0
PEG Ratio 0.46
Piotroski score 7.00
Earnings yield 6.30 %
Sales growth 5Years 15.2 %

Also Check ONGC Share Price Target

Marksans Pharma Quarterly Results

Metric Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Sales 358 330 349 361 363 418 434 453 480 486 500 531 586
Expenses 267 235 272 301 305 354 361 372 403 376 398 417 453
Operating Profit 91 95 77 60 58 64 73 80 77 110 102 114 133
OPM % 25% 29% 22% 17% 16% 15% 17% 18% 16% 23% 20% 21% 23%
Other Income -3 6 6 9 12 15 16 14 18 11 10 19 5
Interest 2 3 1 2 1 5 2 3 2 2 2 2 3
Depreciation 9 1 7 7 9 21 11 14 13 14 14 18 22
Profit before tax 78 97 75 60 60 53 76 78 79 104 97 114 113
Tax % 24% 18% 16% 23% 20% 44% 21% 23% 21% 21% 27% 26% 26%
Net Profit 59 80 63 46 48 30 60 60 62 83 70 84 83
EPS in Rs 1.44 1.94 1.53 1.11 1.18 0.69 1.46 1.51 1.57 1.81 1.52 1.84 1.84

CAGR Report

Compounded Sales Growth:

Time Period Growth Rate
10 Years 16%
5 Years 15%
3 Years 18%
TTM 18%

Compounded Profit Growth:

Time Period Growth Rate
10 Years 19%
5 Years 52%
3 Years 30%
TTM 51%

Stock Price CAGR:

Time Period CAGR
10 Years 20%
5 Years 48%
3 Years 30%
1 Year 126%

Return on Equity:

Time Period ROE
10 Years 20%
5 Years 21%
3 Years 22%
Last Year 19%

Marksans Pharma Shareholding Pattern

Shareholder Type Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoters 48.60% 49.00% 43.85% 43.85% 43.85% 43.85% 43.85%
FIIs 4.06% 4.23% 15.11% 14.90% 15.07% 15.55% 15.57%
DIIs 0.95% 0.96% 1.46% 3.65% 4.02% 4.76% 5.17%
Public 46.38% 45.79% 39.57% 37.60% 37.06% 35.81% 35.40%
No. of Shareholders 2,17,743 2,13,123 1,98,382 1,88,447 2,07,937 2,37,377 2,54,699

Marksans Pharma Share Price Target 2024-2030 Forecast

Year Target
2024 228
2025 276
2026 293
2027 334
2028 370
2029 400
2030 450

Marksans Pharma Share Price Target 2025

Months Target Prices
January 235
February 240
March 230
April 237
May 244
June 240
July 248
August 255
September 252
October 257
November 268
December 276

Marksans Pharma Share Price Target 2026

Months Target Prices
January 280
February 274
March 269
April 271
May 277
June 282
July 285
August 290
September 283
October 284
November 290
December 293

Marksans Pharma Share Price Target 2027

Months Target Prices
January 301
February 293
March 287
April 294
May 300
June 306
July 319
August 311
September 320
October 325
November 329
December 334

Marksans Pharma Share Price Target 2028

Months Target Prices
January 340
February 331
March 326
April 330
May 337
June 344
July 350
August 357
September 363
October 360
November 364
December 370

Marksans Pharma Share Price Target 2029

Months Target Prices
January 363
February 355
March 350
April 357
May 364
June 370
July 374
August 380
September 384
October 389
November 394
December 400

Marksans Pharma Share Price Target 2030

Months Target Prices
January 415
February 402
March 393
April 396
May 405
June 414
July 420
August 429
September 423
October 430
November 440
December 450

Official Website –marksanspharma.com

Leave a Comment